News

Lower blood levels of an enzyme involved in processes such as tissue remodeling and wound healing may help distinguish people with idiopathic angioedema, a form of angioedema that has no obvious cause, from those with hereditary angioedema (HAE) or mast cell-mediated angioedema, a small study in China suggested. Levels…

Once-daily treatment with deucrictibant extended-release (XR) tablets reduced the frequency of swelling attacks among people with hereditary angioedema (HAE) by more than 80% compared with a placebo in a late-stage clinical trial. Moreover, lasting benefits were seen for study participants with different types of the chronic genetic disease.

A woman in her early 20s with systemic lupus erythematosus (SLE), the most common form of the autoimmune disease lupus, developed recurrent episodes of angioedema despite having normal C1 esterase inhibitor (C1-INH) levels and function, according to a case report. Instead, blood tests showed signs that the complement…

The U.S. Food and Drug Administration (FDA) is slated to decide by early next year whether or not to approve a one-time gene-editing therapy to potentially control swelling in hereditary angioedema (HAE). The regulatory agency accepted an application from Intellia Therapeutics seeking approval of its infusion therapy…

Takhzyro (lanadelumab) is a safe and effective long-term preventive treatment that can reduce the frequency of hereditary angioedema (HAE) attacks and improve disease control and quality of life, according to a review of clinical and real-world data. The review, “Lanadelumab Use for Hereditary Angioedema Long-Term…

Biocryst Pharmaceuticals‘ once-daily oral therapy Orladeyo (berotralstat) is now approved in Japan to prevent swelling attacks in children with hereditary angioedema (HAE) as young as 2 years old. Japan’s Ministry of Health, Labor and Welfare (MHLW) first approved Orladeyo in 2021 as a treatment for HAE…

Onvuzosiran, an experimental treatment for hereditary angioedema (HAE) now in Phase 3 testing, has been granted fast track designation from the U.S. Food and Drug Administration (FDA). The FDA grants this status to expedite the development and review of experimental medicines that show potential to address unmet medical needs…

Long-term preventive treatment with Takhzyro (lanadelumab-flyo) — approved in the U.S. and the European Union for nearly a decade — substantially reduces the rate of swelling attacks in people with hereditary angioedema (HAE) treated in routine clinical practice. That’s according to the final results of a Phase 4 study…

An infant with recurrent episodes of swelling in her limbs and around her eyes was ultimately diagnosed with idiopathic angioedema after tests ruled out lymphedema and other potential causes, according to a case report. The 4-month-old girl was initially referred for evaluation for possible lymphedema, a condition in which…

A woman with hereditary angioedema (HAE) gave birth to a healthy baby after being briefly exposed to Orladeyo  (berotralstat) early in her pregnancy, according to a case report from Italy. The woman became pregnant about three months after starting Orladeyo, and the fetus was exposed to the treatment…